Hypofractionation for prostate cancer (Q40004846)

16 September 2017

Hypofractionation for prostate cancer (English)

1 reference

16 September 2017

1 reference

Mark Ritter

1

1 reference

16 September 2017

Jeffrey Forman

2

1 reference

16 September 2017

Patrick Kupelian

3

1 reference

16 September 2017

Colleen Lawton

4

1 reference

16 September 2017

Daniel Petereit

5

1 reference

16 September 2017

1 January 2009

1 reference

16 September 2017

1 reference

16 September 2017

15

1 reference

16 September 2017

1-6

1 reference

16 September 2017

1

1 reference

Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?

16 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Is alpha/beta for prostate tumors really low?

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Carcinoma of the prostate: results of radical radiotherapy (1970-1985).

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

What hypofractionated protocols should be tested for prostate cancer?

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Is the alpha/beta ratio for prostate cancer low?

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

The α/β ratio for prostate cancer: What is it, really?

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3039916

Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue

2 December 2018

1 reference

12 December 2020

Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer

1 reference

12 December 2020

How low is the alpha/beta ratio for prostate cancer?

1 reference

12 December 2020

The Effect of Multiple Small Doses of X Rays on Skin Reactions in the Mouse and a Basic Interpretation

1 reference

12 December 2020

Tumor radioresponsiveness versus fractionation sensitivity

1 reference

12 December 2020

Retrospective study of radiotherapy in early carcinoma of the prostate

1 reference

12 December 2020

Clinical radiobiology of malignant melanoma

1 reference

12 December 2020

Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique

1 reference

12 December 2020

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

1 reference

12 December 2020

Extrapolating hypofractionated radiation schemes from radiosurgery data: regarding Hall et al., IJROBP 21:819-824; 1991 and Hall and Brenner, IJROBP 25:381-385; 1993

1 reference

12 December 2020

A convenient extension of the linear-quadratic model to include redistribution and reoxygenation

1 reference

12 December 2020

Cell kinetic measurements in prostate cancer

1 reference

12 December 2020

Fractionation and protraction for radiotherapy of prostate carcinoma

1 reference

12 December 2020

What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy

1 reference

12 December 2020

Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy

1 reference

12 December 2020

Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer

1 reference

12 December 2020

Hypofractionated radiotherapy with carbon ion beams for prostate cancer

1 reference

12 December 2020

Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy

1 reference

12 December 2020

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience

1 reference

12 December 2020

Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma

1 reference

12 December 2020

Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the CHHiP trial

1 reference

12 December 2020

High-dose single-fraction radiotherapy: exploiting a new biology?

1 reference

12 December 2020

10.1097/PPO.0B013E3181976614

Identifiers

DOI

1 reference

16 September 2017

1 reference

16 September 2017

1 reference